Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside

Ascendis Pharma earnings event and why it matters for shareholders

Ascendis Pharma (NasdaqGS:ASND) recently reported second quarter 2026 results, with sales of €339.29 million and net income of €206.97 million, following a net loss in the same period a year earlier.

See our latest analysis for Ascendis Pharma.

Following the strong second quarter earnings shift into profitability, Ascendis Pharma’s 7 day share price return of 2.38% and 90 day share price return of 5.69% suggest momentum has picked up. However, the year to date share price return of 3.22% points to a more measured longer term move around the current $253.29 level.

If Ascendis Pharma’s recent results have caught your attention, it can help to compare it with other potential growth stories in healthcare. Take the next step and review 41 healthcare AI stocks.

After Ascendis Pharma’s sharp swing into profit and a more modest share price move, the real test now is whether the current valuation still leaves more upside than downside risk for new buyers.

Most Popular Narrative: 19.2% Undervalued

At a last close of $253.29 versus a narrative fair value of $313.36, Ascendis Pharma is framed as materially undervalued, with that view anchored in the TransCon product portfolio.

Broader adoption of YORVIPATH in chronic hypoparathyroidism, with only a small share of eligible U.S. patients currently on therapy and access expanding across more than 30 countries, can widen the treated patient base and support recurring product revenue and operating cash flow.

Read the complete narrative.

Want to see what is assumed behind that upside gap? The narrative leans heavily on rapid revenue expansion, high margins and a premium earnings multiple that lifts the fair value above the current share price.

Result: Fair Value of $313.36 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still clear risks to the Ascendis Pharma story, especially if YORVIPATH uptake slows or if TransCon CNP and Yuviwel approvals and rollouts face delays.

Find out about the key risks to this Ascendis Pharma narrative.

Next Steps

With Ascendis Pharma showing both clear upside drivers and real risk flags, it makes sense to move fast and review the full picture for yourself. A useful place to start is by weighing up the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ascendis Pharma?

If Ascendis Pharma has sharpened your focus, do not stop here. Use the Simply Wall St screener to uncover other opportunities that could fit your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com